He is a graduate of the University of Cambridge (M.Sc. in Bioscience Enterprise) and the Hebrew University of Jerusalem (M.Sc. Neurobiology, BSc Mathematics and Biology).
Gilead Raday previously served as interim CEO of Sepal Pharma, and as a director at TK Signal and Morria Biopharmaceuticals.